INNOPHARMAX INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.75 TWD | +1.94% |
|
+5.70% | -9.48% |
| 19/04 | InnoPharmax Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | InnoPharmax Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 29.13M 900K 75.13M | Sales 2023 | 46.07M 1.42M 119M | Capitalization | 1.65B 51.08M 4.26B |
|---|---|---|---|---|---|
| Net income 2022 | -103M -3.18M -266M | Net income 2023 | -70M -2.16M -181M | EV / Sales 2022 | 32.6 x |
| Net cash position 2022 | 67.02M 2.07M 173M | Net cash position 2023 | 118M 3.66M 305M | EV / Sales 2023 | 33.3 x |
| P/E ratio 2022 |
-9.83
x | P/E ratio 2023 |
-22.6
x | Employees | 34 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.83% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.94% | ||
| 1 week | +5.70% | ||
| Current month | +5.70% | ||
| 1 month | -0.94% | ||
| 3 months | -10.26% | ||
| 6 months | -23.54% | ||
| Current year | -9.48% |
1 week
14.70
16.10
1 month
14.4016.10
Current year
14.4019.95
1 year
14.4034.00
3 years
10.7534.00
5 years
6.9149.45
10 years
6.6991.49
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Hua Hao
CEO | Chief Executive Officer | - | - |
Ssu Ju Chen
DFI | Director of Finance/CFO | - | 01/22/01 |
Yu Tsai Yang
CTO | Chief Tech/Sci/R&D Officer | - | 21/21/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chih Hui Lin
CHM | Chairman | - | - |
Wei Hua Hao
CEO | Chief Executive Officer | - | - |
Han Pin Kuo
BRD | Director/Board Member | - | 29/12/29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/24/06 | 15.75 | +1.94% | 216,476 |
| 03/24/03 | 15.45 | +3.34% | 235,276 |
| 02/24/02 | 14.95 | +0.34% | 21,625 |
| 30/24/30 | 14.9 | 0.00% | 70,151 |
End-of-day quote Taipei Exchange, May 06, 2024
More quotes
Innopharmax Inc is a Taiwan-based company principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company mainly provides generic drugs, including Cyclosporine A, Tacrolimus, Imipenem, Cilastatin, Gadodiamide, Gadopentetate, Levodopa, Carbidopa and Entacapone, as well as new drugs, including Gemcitabine Oral, Bendamustine, AB01001 patch and Carvedilol CR, among others. The Company mainly distributes its products within domestic market.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -9.48% | 45.46M | |
| +21.41% | 43.48B | |
| +21.38% | 22.65B | |
| +14.56% | 14.73B | |
| +14.21% | 13.79B | |
| +48.11% | 12.04B | |
| -8.66% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.75% | 5.47B |
- Stock Market
- Equities
- 4172 Stock